Transcriptome-based machine learning reveals an MCL1 dependency in alveolar soft part sarcoma
A support-vector-regression model trained to infer gene dependencies from RNA-sequencing profiles predicted selective MCL1 dependence in alveolar soft part sarcoma (ASPS), distinct from TFE3-translocation renal cell carcinoma. The authors tested the prediction with CRISPR knockout and the MCL1 inhibitor murizatoclax in two ASPS cell lines; the reported viability effects were greater in ASPS than comparator tRCC lines.
Technology: Transcriptome-based support-vector regression model (RBF kernel; 657 highly predictable gene dependencies)
Publication: Preprint · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Preprint
- Test type: direct test
- Tested: The authors tested the prediction with CRISPR knockout and the MCL1 inhibitor murizatoclax in two ASPS cell lines; the reported viability effects were greater in ASPS than comparator tRCC lines.
- Still unknown: bioRxiv preprint, not peer reviewed as stated by PMC. Validation was in two ASPS cell lines with CRISPR and inhibitor assays; it does not establish patient benefit or clinical efficacy. The model nominates dependencies and is not a functional screen itself.
- AI role: The model predicted per-gene dependency scores from tumor/cell-line expression profiles and prioritized selective vulnerabilities. The study then tested MCL1 dependence in ASPS using three distinct sgRNAs and murizatoclax; those experiments, rather than the prediction alone, provide the reported validation.
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC11527139/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.